Copyright © 2021 pubrica. All rights reserved 1 1

How to Overcome Regulatory and Ethical

Challenges Regarding Medical Device

Dr. Nancy Agnes, Head, Technical Operations, Pubrica, sales@pubrica.com

In Brief

Biotechnological advancements in medical devices

can intensify risks and introduce new types of risk,

despite their potential to greatly benefit health.

Therapeutic products control is our primary tool for

handling these threats. As these developments

advance, the current regulatory approach is likely to

be called into question.

Keywords: Therapeutic products regulation,

regulatory writing, standardised devices, Healthcare

research, medical data collection.

I. INTRODUCTION

The below are the top ten ethical questions, in order of

priority, as viewed by the participants:(1)Equity of

resources, (2) Patients' Rights, (3Patient Safety, (4) )

Confidentiality of the patients, (5)Ethics of

privatisation, (6)Conflict of Interests, (7)Dealing with

the opposite sex, (8)Informed Consent, (9) Beginning

and end of life, and (10) Healthcare team ethics.

II. ETHICS AND THE PURPOSE OF

THERAPEUTIC GOODS REGULATION

Therapeutic products regulation has two roles, which

are often at odds with one another. Control strives to

preserve the public's health and welfare while enabling

or also promoting useful technologies to enter the

market as soon as possible. The expectation that

suppliers show proof of a product's protection and

efficacy is a significant part of how modern systems

meet these goals. On the one side, this safeguards

people from consuming goods that are harmful or

ineffective. On the other hand, it implies that market

success must be founded on sound science, with quality

creativity rewarded.

If evidentiary expectations are too uncertain, regulators'

ability to protect patients may be endangered; if they

are too high, patients may be denied access to new

developments unnecessarily.

III. PROBLEMS OF EVIDENCE ABOUT DEVICES

The immense ethical challenge with consumer

regulation is that we currently tolerate a high risk

during the business acceptance period due to data

gathering issues and the operational requirements of a

regulatory report writing framework related to products,

not that the stakes have been measured appropriately.

Another hand, many buyers conclude that the

commodity on the market has been adequately tested

for protection and efficacy.

IV. NEW CHALLENGES

Emerging innovations add to the complexity of these

already complicated problems. I'll write to two of them.

1. First, machines are becoming more computerised, with many, such as pacemakers and insulin pumps,

incorporating automation into their operations. It

has various advantages, including automation of

tasks for smoother management; improved

calibration of equipment to patients' needs; a

collection of physiological data of therapeutic

significance; and remote, therefore more effective,

system modification.

The use of software in or as a diagnostic system

exacerbates current problems while also adding new

ones. It ensures that devices may be updated ever more

regularly. These changes can affect the functionality of

devices already in use by patients or even implanted in

their bodies. It would become much more challenging

to ensure the technologies remain secure and

prosperous as they grow.Manufacturers will be held

more responsible for device functionality in the long

term. Software introduces additional types of risks,

such as predicting how functionality will be

compromised when used in combination with various

technical technologies and when applied to multiple

clinical scenarios.Another significant and relatively

recent danger concerns cybersecurity: the threat of

computers being compromised and used to damage

their owners.

Customisation, once again, creates new problems.

Given the unparalleled simplicity with which this

manufacturing method can be used, it could be

mailto:sales@pubrica.comhttps://pubrica.com/academy/statistical/new-medical-device-regulations/https://pubrica.com/services/physician-writing-services/

Copyright © 2021 pubrica. All rights reserved 2 2

impossible for regulators to keep track of all

applications.

2. Increased system customisation, especially by 3D printing and computer-aided design, is a second

evolving possibility. Implants often used, such as

artificial hips, can now be designed in proportions

more closely matched to individual conditions.

Personalised models can even be explicitly

modelled on patient physiology. It seems to help

patients on the surface; however, gathering

rigorous proof of protection and usefulness for

custom devices is much more complex than

standardised devices. Customisation is profoundly

at odds with the most substantial evidence for

regulatory purposes, created from populations of

study subjects that undergo a standardised

intervention. As a result, customisation exacerbates

the difficulty of finding good data for devices.

Custom instruments have typically been used by

testing laws or legal exemptions in the past. The

more customisation is used, the less suitable this

becomes.

V. QUESTIONING CURRENT APPROACHES

If technological advancements continue to pressure the

existing system, it's worth considering any other

options for interface control. Some innovations can

eliminate inequities, such as using 3D printing to

include lower-tech electronics in low-income nations.

Still, this potential will not be appreciated as long as the

research is incentivised today. Healthcare research is

focused mainly on commercially viable goods that can

disregard changes that may be achieved by societal or

structural change.

VI. LIMITATIONS OF THE STUDY

The willingness to generalise the findings is a critical

drawback. First, the report excluded smaller

underserved rural hospitals, which may have revealed a

different medical data collection of ethics concerns,

even though equality in resource availability was

identified as one of the top five problems.

https://pubrica.com/academy/statistical/new-medical-device-regulations/https://pubrica.com/sevices/research-services/https://pubrica.com/services/medical-data-collection/

Copyright © 2021 pubrica. All rights reserved 3 3

Second, despite the study's efforts to include non-

clinicians, male clinicians' dominance in the survey

may have tainted the findings and conclusions. It may

also clarify why no ethical concerns about paramedical

personnel and their interactions with doctors were

raised.

VII. CONCLUSION

The central ethical issues as alleged by the participants

were: (1) Patients' Rights, (2) Equity of resource

distribution, (3) Confidentiality of patients, (4) Patient

Safety, (5) Conflict of Interests, (6) Ethics of

privatisation, (7) Informed Consent, (8) Dealing with

the opposite sex, (9) Beginning and end of life, and (10)

Healthcare Team Ethics.This collection, however, was

not exhaustive. This study's findings were meant to be

compared to those of another task. Since the differences

in culture and healthcare systems, discrepancies were

predicted.

REFERENCES

1. Gibbs JN, et al. 2014. 510(k) statistical patterns. Medical Device and Diagnostic Industry, 2 Dec,

https://www.mddionline.com/510k-statistical-

patterns.

2. Roger WA, Hutchison K. 2017. Hips, knees, and hernia mesh: When does gender matter in surgery?

International Journal of Feminist Approaches to

Bioethics 10(1):148-174.

3. Hutchison K, Sparrow R. 2017. Ethics and the cardiac pacemaker: More than just end-of-life

issues. Europace, online first

doi:10.1093/europace/eux019.

4. IMDRF Software as a Medical Device (SaMD) Working Group. 2014. "Software as a Medical

Device": Possible Framework for Risk

Categorisation and Corresponding Considerations.

International Medical Device Regulators Forum,

http://www.imdrf.org/docs/imdrf/final/technical/im

drf-tech-140918-samd-framework-risk-

categorization-141013.pdf.

https://www.mddionline.com/510k-statistical-patternshttps://www.mddionline.com/510k-statistical-patterns